BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 8558225)

  • 1. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women.
    Powles TJ; Hickish T; Kanis JA; Tidy A; Ashley S
    J Clin Oncol; 1996 Jan; 14(1):78-84. PubMed ID: 8558225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial.
    Cheung AM; Tile L; Cardew S; Pruthi S; Robbins J; Tomlinson G; Kapral MK; Khosla S; Majumdar S; Erlandson M; Scher J; Hu H; Demaras A; Lickley L; Bordeleau L; Elser C; Ingle J; Richardson H; Goss PE
    Lancet Oncol; 2012 Mar; 13(3):275-84. PubMed ID: 22318095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tamoxifen reduces bone turnover and prevents lumbar spine and proximal femoral bone loss in early postmenopausal women.
    Ward RL; Morgan G; Dalley D; Kelly PJ
    Bone Miner; 1993 Aug; 22(2):87-94. PubMed ID: 8251768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years.
    Love RR; Barden HS; Mazess RB; Epstein S; Chappell RJ
    Arch Intern Med; 1994 Nov; 154(22):2585-8. PubMed ID: 7979855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.
    Coleman RE; Banks LM; Girgis SI; Kilburn LS; Vrdoljak E; Fox J; Cawthorn SJ; Patel A; Snowdon CF; Hall E; Bliss JM; Coombes RC;
    Lancet Oncol; 2007 Feb; 8(2):119-27. PubMed ID: 17267326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis].
    Liu JL; Zhu HM; Huang QR; Zhang ZL; Li HL; Qin YJ; Zhang Y; Wei DL; Lu JH; Liu H; Chen XP; Liu YJ; Ekangaki A; Zheng YM; Diez-Perez A; Harpe K
    Zhonghua Yi Xue Za Zhi; 2004 Feb; 84(4):269-73. PubMed ID: 15059505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group.
    Hosking D; Chilvers CE; Christiansen C; Ravn P; Wasnich R; Ross P; McClung M; Balske A; Thompson D; Daley M; Yates AJ
    N Engl J Med; 1998 Feb; 338(8):485-92. PubMed ID: 9443925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
    Gnant M; Mlineritsch B; Luschin-Ebengreuth G; Kainberger F; Kässmann H; Piswanger-Sölkner JC; Seifert M; Ploner F; Menzel C; Dubsky P; Fitzal F; Bjelic-Radisic V; Steger G; Greil R; Marth C; Kubista E; Samonigg H; Wohlmuth P; Mittlböck M; Jakesz R;
    Lancet Oncol; 2008 Sep; 9(9):840-9. PubMed ID: 18718815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of tibolone and fluoride displays a pronounced effect on bone mineral density in postmenopausal osteoporotic women.
    Reginster JY; Agnusdei D; Gennari C; Kicovic PM
    Gynecol Endocrinol; 1999 Oct; 13(5):361-8. PubMed ID: 10599554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women.
    Grey AB; Stapleton JP; Evans MC; Tatnell MA; Ames RW; Reid IR
    Am J Med; 1995 Dec; 99(6):636-41. PubMed ID: 7503087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Exemestane and Tamoxifen treatment on bone texture analysis assessed by TBS in comparison with bone mineral density assessed by DXA in women with breast cancer.
    Kalder M; Hans D; Kyvernitakis I; Lamy O; Bauer M; Hadji P
    J Clin Densitom; 2014; 17(1):66-71. PubMed ID: 23562130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhaled corticosteroids reduce bone mineral density in early postmenopausal but not premenopausal asthmatic women.
    Fujita K; Kasayama S; Hashimoto J; Nagasaka Y; Nakano N; Morimoto Y; Barnes PJ; Miyatake A
    J Bone Miner Res; 2001 Apr; 16(4):782-7. PubMed ID: 11316007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between bone turnover biomarkers, mandibular bone mineral density, and systemic skeletal bone mineral density in premenopausal and postmenopausal Indian women.
    Makker A; Singh MM; Mishra G; Singh BP; Jain GK; Jadhav S
    Menopause; 2012 Jun; 19(6):642-9. PubMed ID: 22240638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study.
    Kristensen B; Ejlertsen B; Dalgaard P; Larsen L; Holmegaard SN; Transbøl I; Mouridsen HT
    J Clin Oncol; 1994 May; 12(5):992-7. PubMed ID: 8164053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.
    McClung MR; Wasnich RD; Recker R; Cauley JA; Chesnut CH; Ensrud KE; Burdeska A; Mills T;
    J Bone Miner Res; 2004 Jan; 19(1):11-8. PubMed ID: 14753731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status.
    Vehmanen L; Elomaa I; Blomqvist C; Saarto T
    J Clin Oncol; 2006 Feb; 24(4):675-80. PubMed ID: 16446340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in bone mineral density during and after 3 years' use of tamoxifen or toremifene.
    Tiitinen A; Nikander E; Hietanen P; Metsä-Heikkilä M; Ylikorkala O
    Maturitas; 2004 Jul; 48(3):321-7. PubMed ID: 15207898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.
    Jolly EE; Bjarnason NH; Neven P; Plouffe L; Johnston CC; Watts SD; Arnaud CD; Mason TM; Crans G; Akers R; Draper MW
    Menopause; 2003; 10(4):337-44. PubMed ID: 12851517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of dehydroepiandrosterone on lumbar spine bone mineral density in patients with quiescent systemic lupus erythematosus.
    Hartkamp A; Geenen R; Godaert GL; Bijl M; Bijlsma JW; Derksen RH
    Arthritis Rheum; 2004 Nov; 50(11):3591-5. PubMed ID: 15529389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
    Bone HG; Bolognese MA; Yuen CK; Kendler DL; Wang H; Liu Y; San Martin J
    J Clin Endocrinol Metab; 2008 Jun; 93(6):2149-57. PubMed ID: 18381571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.